Work

Abstract 254: The PARP1-selective inhibitor and trapper saruparib achieves extended PARP1 target engagement in vitro , in vivo and in the clinic.

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-254

Authors: Mark Robert Albertella, Giuditta Illuzzi, Anna D. Staniszewska, Domenic Pilger, Sophie Cooke, Spiros Linardopoulos, Anna Beckett, Christopher Stubbs, Ganesh Moorthy, Mark J. O'Connor

Institution: AstraZeneca (United Kingdom)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148872433

Cites:

Cited by:

Related to: